Three GLP-1 drugs are best at helping obese and overweight people drop weight, including one that hasn't yet been approved ...

Eli Lilly’s popular anti-obesity drug Zepbound could get a sales boost after the U.S. Medicare program decided to pay for its use to treat sleep apnea. The Centers f ...

Over her three-decade career, weight management physician Dr. Sarah Ro has seen hundreds of patients. Many of them are on ...

It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...

According to BMO Capital Markets, Medicare coverage of Lilly’s Zepbound opens the door to using secondary indications to ...

Topline data were announced from the AUDACITY trial evaluating the Allurion Gastric Balloon, a swallowable, procedureless intragastric balloon, in adults with obesity.

Eli Lilly's obesity drug Zepbound can now be covered by government-backed Medicare insurance plans for use in sleep apnea, ...

Maridebart cafraglutide, a novel injectable GIP receptor antagonist/GLP-1 receptor agonist, reduced body weight by ...

Medicare drug plans can now cover Eli Lilly & Co.'s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that's expected to prove a big boost for the drug company.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 484.89% and ...

Holiday weight gain hits home for many come January. These days, folks making resolutions to slim down and get fit have an ...